Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Open Access
- 1 October 2012
- journal article
- research article
- Published by Elsevier BV in Cell
- Vol. 151 (2), 344-355
- https://doi.org/10.1016/j.cell.2012.08.038
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic ChemotherapyScience, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+CD8+thymocytesProceedings of the National Academy of Sciences of the United States of America, 2010
- MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterpartsThe Journal of cell biology, 2009
- Targeting DNA topoisomerase II in cancer chemotherapyNature Reviews Cancer, 2009
- BAX activation is initiated at a novel interaction siteNature, 2008
- Identification of a Hierarchy of Multipotent Hematopoietic Progenitors in Human Cord BloodCell Stem Cell, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Cell DeathCell, 2004
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001